2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Breast Neoplasms
2046
Neoplasms
1460
Carcinoma, Non-Small-Cell Lung
1363
Prostatic Neoplasms
1106
Multiple Myeloma
872
Leukemia, Myeloid, Acute
772
Colorectal Neoplasms
713
Neoplasm Metastasis
704
Lung Neoplasms
697
Melanoma
688
Lymphoma
666
Leukemia
596
Lymphoma, Non-Hodgkin
593
Leukemia, Lymphocytic, Chronic, B-Cell
535
Ovarian Neoplasms
535
Pancreatic Neoplasms
500
Precursor Cell Lymphoblastic Leukemia-Lymphoma
485
Recurrence
474
Myelodysplastic Syndromes
425
Lymphoma, Follicular
418
Carcinoma, Renal Cell
412
Head and Neck Neoplasms
408
Glioblastoma
380
Lymphoma, Large B-Cell, Diffuse
379
Brain Neoplasms
376
Hodgkin Disease
354
Carcinoma, Hepatocellular
333
Squamous Cell Carcinoma of Head and Neck
326
Lymphoma, Mantle-Cell
306
Sarcoma
286
Interventions
amatuximab
1
Pemetrexed
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Severe combined immunodeficiency with sensitivity to ionizing radiation
×
Clear all
NCT02357147
2020-03-17
ARTEMIS
Morphotek
Phase 2
Terminated
124 enrolled
10 charts